FDA-Approved Weight Loss Medications

Long-Term FDA-Approved Medications (>12 weeks use)

• The American College of Gastroenterology recommends Liraglutide 3.0 mg (Saxenda) for weight loss, with a 5.4% mean weight loss at 56 weeks, and requires dose escalation from 0.6 mg daily, increasing by 0.6 mg weekly up to 3.0 mg 1
• The American Gastroenterological Association suggests that Phentermine/Topiramate ER (Qsymia) is a fixed-dose combination targeting multiple pathways, with a 6.6% mean weight loss at 1 year, and is contraindicated in cardiovascular disease, pregnancy, glaucoma, and hyperthyroidism 1
• The American Heart Association recommends Orlistat (Xenical 120 mg/Alli 60 mg) for weight loss, which blocks ~30% of dietary fat absorption, with a 3.1% mean weight loss at 1 year, and requires multivitamin supplementation (fat-soluble vitamins A, D, E, K) 1

Indications for Pharmacotherapy

• The American Diabetes Association recommends prescribing weight loss medications for patients with BMI ≥30 kg/m² OR BMI ≥27 kg/m² with weight-related comorbidities (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea) 2

Clinical Decision Algorithm

• The American College of Cardiology suggests that Semaglutide 2.4 mg weekly OR Tirzepatide is the preferred first-line choice for most patients due to superior efficacy and cardiovascular benefits 3

Monitoring and Efficacy Assessment

• The American Association of Clinical Endocrinologists recommends assessing monthly for the first 3 months, then quarterly, and discontinuing or changing medication if <5% weight loss after 3 months at therapeutic dose 2
• The Endocrine Society suggests continuing medication beyond reaching weight loss goals to maintain benefits, as obesity is a chronic disease requiring indefinite treatment 3

Weight Loss Medication Guidelines

Patient Selection and First-Line Medication Options

• The American Gastroenterological Association recommends that patients with a BMI ≥27 kg/m² and weight-related comorbidities, such as type 2 diabetes, should be considered for weight loss pharmacotherapy 4
• Patients with obesity and constipation may benefit from orlistat due to its gastrointestinal effects, and it is also suitable for those with cardiovascular contraindications to sympathomimetic agents or limited financial resources 5, 4, 6
• The American College of Gastroenterology suggests that phentermine/topiramate ER is an alternative first-line option when GLP-1 agonists are contraindicated or unavailable, with a mean weight loss of 6.6% at 1 year 5
• Orlistat is a budget-friendly first-line option that blocks ~30% of dietary fat absorption, with a mean weight loss of 3.1% at 1 year, and requires multivitamin supplementation 5

Off-Label First-Line and Monitoring

• Phentermine monotherapy is commonly prescribed off-label for weight loss, with a weight loss of 6.0 kg at 28 weeks, and 46% of patients achieving ≥5% weight loss 6, 4
• The American Gastroenterological Association recommends that patients on phentermine should be monitored for blood pressure and heart rate, and monthly pregnancy testing should be ensured for women of reproductive age on phentermine/topiramate ER 6, 4

Medication Contraindications and Pitfalls

• The American Heart Association advises against combining phentermine with other weight loss medications, and exceeding recommended phentermine doses when tolerance develops 4
• The American College of Cardiology recommends avoiding β-blockers as antihypertensives in patients with obesity, as they promote weight gain 4

Effective Weight Loss Medications

First-Line Pharmacotherapy Options

• The American Gastroenterological Association conditionally recommends against orlistat use given its modest efficacy and side effect profile, with approximately 2.8-4.8% mean weight loss at one year 7, 8
• Phentermine-Topiramate ER delivers the highest weight loss among FDA-approved obesity medications at 6.6-9.8% total body weight loss at one year 7
• Naltrexone-Bupropion ER produces approximately 4.8-6% weight loss at 56 weeks, and may be particularly useful for patients with comorbid depression, desire for smoking cessation, or alcohol use reduction 7, 8
• Orlistat achieves only 2.8-4.8% mean weight loss with frequent gastrointestinal adverse effects, but remains appropriate when other medications are contraindicated, unavailable, or unaffordable 7, 8

Clinical Implementation Algorithm

• The American College of Cardiology recommends that all medications must be combined with reduced-calorie diet and increased physical activity, with high-intensity behavioral interventions significantly enhancing outcomes 9

Critical Safety Considerations

• With orlistat, a daily multivitamin containing fat-soluble vitamins A, D, E, K should be prescribed, taken 2 hours apart from orlistat due to malabsorption risk, and an FDA warning exists for potential serious liver injury 7, 8
• Weight regain typically occurs rapidly upon discontinuation of weight loss medication, highlighting the need for long-term treatment 10

Pharmacotherapy Eligibility and Management for Overweight Adults without Comorbidities

Eligibility Criteria for Anti‑Obesity Medication

• Pharmacologic treatment is recommended only for adults with BMI ≥ 30 kg/m² (obesity) when no weight‑related comorbidities are present, or for those with BMI ≥ 27 kg/m² together with at least one comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea【11】.
• In a 46‑year‑old man with BMI = 26.5 kg/m² and no comorbidities, anti‑obesity medication is not indicated because the BMI threshold is not met【11】.

Clinical Rationale for Restricting Pharmacotherapy

• Approved weight‑loss drugs achieve only modest reductions in body weight, typically 3 %–6 % of total body weight【11】.
• All currently approved agents have adverse‑effect profiles that must be justified by a significant health risk to the patient【12】【13】.
• The risk‑benefit balance favors medication use only when the BMI level or associated comorbidities constitute a substantial threat to morbidity or mortality【11】.

Recommended Lifestyle‑First Strategy

• Physical activity: Encourage ≥200–300 minutes per week of moderate‑intensity exercise (greater than the standard 150 minutes)【11】.
• Caloric deficit: Implement a structured deficit of ≈500 kcal/day, targeting a total daily intake of 1,200–1,800 kcal【11】.
• Follow‑up contact: Arrange monthly interactions (in‑person visits, phone calls, texts, or app‑based communication) to sustain adherence【11】.
• Professional support: Involve a registered dietitian or health‑coach for intensive dietary and behavioral counseling【11】.

Common Clinical Pitfall to Avoid

• Do not prescribe phentermine or other weight‑loss agents when BMI criteria are not satisfied; doing so exposes patients to unnecessary cardiovascular risks (elevated heart rate and blood pressure) and lacks evidence of benefit in simple overweight individuals【11】.
• Such prescribing can also foster medication dependence, especially when lifestyle modifications would be sufficient【12】【13】.

Monitoring and Re‑evaluation

• Weight monitoring: Measure body weight monthly for the first 3 months of intensive lifestyle intervention【11】.
• Threshold for reconsideration: If a patient fails to achieve ≥5 % weight loss after 3–6 months of intensive lifestyle changes, reassess for emerging comorbidities that might justify pharmacologic therapy【11】.